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Key points:  35 
• The burden of cirrhotic Non-alcoholic Steatohepatitis (NASH) from the patient 36 
perspective remains poorly understood 37 
• We conducted a targeted literature review to identify burden of disease and HRQoL 38 
impairment among patients with NASH-related compensated cirrhosis. 39 
• A quality assessment of specific Patient Reported Outcome Measures (PROMs) was 40 
conducted. 41 
• Patients with NASH-related compensated cirrhosis are reported to suffer from lower 42 
HRQoL than non-cirrhotic NASH patients and the general population with respect to 43 
physical health/functioning, emotional health and worry, and mental health. 44 
• The most commonly used PROMs do not comply with current industry or regulatory 45 
standards for PROMs and/or are not validated for use in a cirrhotic NASH population. 46 
• The lack of studies that include qualitative insights in this population mandates 47 
further exploration and research. 48 
Lay Summary: 49 
It is not well understood how having non-alcoholic fatty liver disease cirrhosis affects a 50 
person’s everyday wellbeing and quality of life. Some research has been done with patients 51 
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who have early stages of liver disease but not people with cirrhosis. A team of researchers 52 
gathered and read research papers to try and find out what the problems were for patients 53 
and if there were any tools or questionnaires used by health professionals to measure or 54 
record their problems. 55 
It was found that patients with non-alcoholic fatty liver disease cirrhosis tended to have 56 
poorer health than liver patients without cirrhosis. But there was not very much information 57 
from patients themselves and, there were no tools or questionnaires just for this group of 58 
patients. We would like to talk to more patients with non-alcoholic fatty liver disease 59 
cirrhosis to help develop a tool/questionnaire which would help future patients.   60 
Graphical abstract: 61 
62 
  63 




The inflammatory form of non-alcoholic fatty liver disease (NAFLD), non-alcoholic 66 
steatohepatitis (NASH), is known to have a negative impact on patients’ health-related 67 
quality of life (HRQoL), even before progression to cirrhosis has occurred. Previous work has 68 
been undertaken to develop a Patient Reported Outcome Measure (PROM) to assess the 69 
impact and burden of disease in the non-cirrhotic NASH patient. The burden of cirrhotic 70 
NASH from the patient perspective remains poorly understood. A targeted literature review 71 
was conducted to identify burden of disease and HRQoL impairment among patients with 72 
NASH-compensated cirrhosis.  73 
Methods 74 
The review sought first to identify humanistic burden of disease from the perspective of 75 
patients with diagnosed NASH-cirrhosis and, secondly, to identify generic or disease-specific 76 
PROMs used to assess the impact of NASH-cirrhosis. Searches were conducted in 77 
bibliographical databases, grey or unpublished literature, liver disease websites, support-78 
group websites and online blogs. A quality assessment of specific PROMs was conducted. 79 
Results  80 
Patients with NASH-cirrhosis are reported to suffer from lower HRQoL than non-cirrhotic 81 
NASH patients and the general population with respect to physical health/functioning, 82 
emotional health and worry, and mental health. Thirteen PROMs were identified, of which 83 
four were liver-disease specific: CLDQ, CLDQ-NAFLD, LDQOL and LDSI. The most commonly 84 
used measures do not comply with current industry or regulatory standards for PROMs 85 
and/or are not validated for use in a cirrhotic NASH population. 86 
Conclusions 87 
Patients with NASH-cirrhosis have lower HRQoL and poorer physical health than non-88 
cirrhotic NASH patients. However, the literature lacked detail of everyday impact on 89 
patients’ lives. Currently, a number of PROMs are available to measure the impact of the 90 
disease in patients with chronic liver conditions. The lack of studies that include qualitative 91 
insights in this population mandates further exploration and research.  92 
 93 
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Background 98 
Non-alcoholic fatty liver disease (NAFLD) is the most common liver condition worldwide, 99 
affecting approximately a quarter of the adult population (1). NAFLD represents a spectrum 100 
of liver disease, ranging from simple steatosis (non-alcoholic fatty liver, NAFL) to the 101 
inflammatory form, non-alcoholic steatohepatitis (NASH). NAFLD is strongly associated with 102 
obesity, type 2 diabetes mellitus and other features of the metabolic syndrome but, as its 103 
name suggests, occurs in the absence of excessive alcohol consumption (2). Although only a 104 
subset of patients progress to advanced liver disease (2, 3), the transition from NAFL to 105 
NASH promotes hepatic fibrosis (scarring) that, unchecked, may lead to cirrhosis and 106 
consequently increased morbidity and mortality (2, 4).  107 
At present, there are no regulatory approved pharmacological treatments for NAFLD and so 108 
management focusses on lifestyle modification to effect weight loss and interventions that 109 
reduce cardiovascular risk (5, 6). In light of this, there is substantial interest in developing 110 
pharmacological therapies targeting liver disease in patients with NASH. Much work is 111 
underway to define clinically meaningful endpoints for clinical trials in NASH that directly 112 
measure how patients feel, function and survive (7, 8). The severity of NAFLD can be defined 113 
based upon the extent of hepatic fibrosis.  Hepatic Fibrosis diagnosed on liver biopsy is 114 
measured using a semi-quantitative histological scoring system where fibrosis severity is 115 
expressed as F0 (normal) to F4 (cirrhosis) (9). Even once F4 is reached, compensated 116 
cirrhosis represents a relatively asymptomatic histological condition characterised by diffuse 117 
fibrosis and nodule formation but with relatively preserved hepatic function that is 118 
physiologically sufficient under non-stressed conditions. In contrast, later decompensated 119 
cirrhosis describes a more severe phase of disease during which the function of the liver is 120 
severely impaired and patients experience overt complications that may include: jaundice, 121 
ascites, hepatic encephalopathy and variceal haemorrhage (10). Whilst primary outcome 122 
measures of efficacy in clinical trials are largely focussed on histological changes that serve 123 
as surrogates for hard clinical endpoints, (11, 12), these measures fail to capture the impact 124 
of the disease from a patient perspective. There is an increased focus on the patient’s 125 
subjective perception of the impact of disease and its treatment on his or her daily life, 126 
including emotional, social and physical functioning and well-being – this is referred to as 127 
health-related quality of life (HRQoL) (13, 14).  128 
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Patient-reported outcomes (PRO) is an umbrella term describing the measurement of any 129 
aspect of a patient’s health status that comes directly from the patient without 130 
interpretation from anyone else (15); this can range from symptom frequency, duration, or 131 
severity to activities of daily living or more complex issues of HRQoL. A PRO Measure 132 
(PROM) has the potential to provide a method with which to assess the impact and burden 133 
of NASH from a patient point of view. Moreover, there is an increasing need to highlight the 134 
value and utility of such a PRO among practitioners and specialists as there is uncertainty in 135 
how best to assess liver fibrosis (16). In addition, regulatory bodies such as the United States 136 
Food and Drug Administration (FDA) and the European Medicines Agency (EMA), have an 137 
expectation that regulatory submissions for new medicines will include information on the 138 
impact of interventions from the patient perspective (17). Whilst both FDA and EMA have 139 
released documents to improve the quality of PROMs used in support of product labelling 140 
claims, the FDA has established guidance to describe what evidence is required to support 141 
the development of PROMs intended for use in label claims (15). For both agencies, the 142 
provision of PRO data generated via well-developed, psychometrically robust, standardised 143 
PROMs is now an essential component of most regulatory submissions. 144 
Previously, a novel condition-specific PROM was developed by a NASH-PRO Task Force. The 145 
“NASH-CHECK” PROM was developed and tested in non-cirrhotic NASH patients (fibrosis 146 
stages F0-F3) (18, 19). However, as alluded to earlier, the symptom burden of compensated 147 
cirrhosis due to NASH (fibrosis stage F4) from the patient perspective is not well 148 
understood. Building on the work conducted whilst developing NASH-CHECK, and to support 149 
future development of this PROM in NASH-cirrhosis, a literature review was undertaken. 150 
The objectives of this review were twofold: 151 
a. To identify the humanistic burden of disease and impairment of HRQoL in patients with 152 
diagnosed NASH and compensated cirrhosis expressed histologically as fibrosis stage F4 153 
based on NASH Clinical Research Network (CRN) categorisation (9) from the perspective 154 
of patients, clinicians and carers.  155 
b. To identify which generic and disease-specific PROMs have been used to assess the 156 
impact of disease among this target population and critically appraise the validity of 157 
these PROMs in accordance with FDA guidance for PROMs intended for use in label 158 
claims. 159 
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Methods 160 
A review protocol was designed and developed by the authors and in consultation with an 161 
information specialist (FB). The protocol included inclusion and exclusion criteria; search 162 
strategy; study selection and data extraction; data synthesis and presentation of results and, 163 
dissemination plans. 164 
Search strategy and eligibility criteria 165 
A search strategy was designed, incorporating information from searches conducted by the 166 
NASH-PRO Task Force as well as published guidance (20).  The following elements were 167 
addressed in separate searches: (i) the humanistic burden of NASH-cirrhosis, and (ii) PROMs 168 
used to assess NASH-cirrhosis.  The following were considered: 169 
o Population (for both searches):   170 
 Adult patients diagnosed with NASH-cirrhosis.  The single term 171 
“cirrhosis” was explored, but it retrieved a vast amount of 172 
literature, which was not related to NAFLD as the causative 173 
aetiology so “cirrhosis” was used as a search term only in 174 
connection with NASH or NAFLD. 175 
o Outcomes (for the first search):   176 
 Patient-reported health-related quality of life 177 
 Patient/carer/clinician-reported symptoms   178 
o Outcomes (for the second search):   179 
 PROM - liver-specific 180 
 PROMs - NASH specific  181 
 PROMs - generic instruments 182 
The search strategy was designed in MEDLINE using Medical Subject Headings (MeSH) 183 
headings and keywords, and the thesaurus headings and syntax were translated 184 
appropriately to other databases.  The following databases were searched from their 185 
inception dates on 28
th
 March 2018 for search addressing objective (a), and 15
th
 June 2018 186 
for search addressing objective (b).  187 
• MEDLINE (OVID) 1946 to March 2018 week 3 (search 1) / June week 2 (search 2) 188 
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• MEDLINE (OVID) Epub Ahead of Print, In-Process & Other Non-Indexed Citations, 189 
Ovid MEDLINE(R) Daily  190 
• Embase (OVID) 1974 to 2018 Week 13 (search 1) / Week 24 (search 2) 191 
• PsycINFO 1806 to March 2018 Week 3 2018 (search 1) / June week 2 (search 2) 192 
Both searches were restricted to papers published in English. All types of studies including 193 
case reports were included.  Example search strategies are available in the supplementary 194 
material - Appendix 1. The reference lists of the final included studies were also searched 195 
for additional relevant papers. Search results were downloaded from the databases into 196 
Endnote and de-duplicated. 197 
A search of the grey or unpublished literature and resources was carried out. The search 198 
terms: ‘adults with NASH F4’ or ‘NASH cirrhosis’ or ‘NAFLD cirrhosis’ were entered into Liver 199 
disease websites, liver patient support group websites and online blogs search functions. 200 
Relevant extracts from the grey literature sources were copied and saved in a Word 201 
document.  202 
Titles and abstracts were screened independently and agreed by two members of the study 203 
team). Endnote software (21) was used for managing the data and Rayyan software (22) for 204 
the screening process. Irrelevant studies were excluded and full texts were independently 205 
screened by two reviewers (LM and MB) based on the inclusion criteria, and study search 206 
results extracted and recorded. In cases of disagreement, a third reviewer (LV) was 207 
consulted to arbitrate. For included studies data extraction forms developed for a similar 208 
review for F1-3 disease used as part of the NASH-CHECK study were used.  209 
Data synthesis  210 
Objective a: humanistic burden of NASH-cirrhosis 211 
In order to provide an overall picture of current knowledge from a heterogeneous sample of 212 
studies; a narrative synthesis (23) was conducted. The HRQoL impacts - where not 213 
definitively reported -were interpreted by and discussed with the research team. 214 
Objective b: PROMs used in NASH-cirrhosis population 215 
The PROMs identified as being used in this patient population were critically assessed to 216 
determine their validity for the target population in relationship to PROM development 217 
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guidance (availability and quality of evidence related to the qualitative development and 218 
psychometric validation). Specifically, the review considered the FDA’s evidence 219 
requirements for reviewing instruments intended to support a label claim in the USA. A 220 
focused quality assessment was conducted for the PROMs that were most likely to meet the 221 
FDA requirements.   222 
Quality assessment 223 
A quality assessment of PROMs identified from the literature was conducted using US FDA 224 
guidance (15) and COSMIN guidelines (24) for reviews of PRO measures. The FDA guideline 225 
sets out specific requirements for the development of PROMs and describes in detail how 226 
the FDA evaluates existing and newly developed tools that are used in clinical trials or 227 
support drug approvals for product labelling. The COnsensus-based Standards for the 228 
selection of health Measurement INstruments (COSMIN) initiative’s checklist was presented 229 
in 2010 as a comprehensive methodological guideline for systematic review of PROMs (23). 230 
The assessment reviewed the PROMs, with particular reference to the quality of the 231 
available evidence to support the use of the instruments for inclusion in a label claim.  The 232 
factors considered in line with FDA recommendations (16) and COSMIN guideline (23) as 233 
properties relevant for the assessment of PROM are supplied in the supplementary material 234 
– Appendix 2, Supplementary Table 1.  235 
Results 236 
Study selection 237 
A total of 26 data sources and five eligible reports from liver disease websites and patient 238 
blogs reporting impact of NASH-cirrhosis and HRQoL impairment were included in this 239 
review.   The PRISMA diagram in Figure 1 described the results of the searching and 240 
screening process for Objective (a). 241 
Many studies did not distinguish NASH-cirrhosis from other aetiologies of cirrhosis, for 242 
example, alcoholic liver disease.  Some studies reported finding no differences in the results 243 
between liver diseases of differing aetiologies (14, 25, 26).   244 
For PROMs used in NASH-cirrhosis patients, 20 relevant data sources were included.  Full 245 
details of results and screening are shown in Figure 2.  246 
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   247 
 248 
  249 
Fig 1: PRISMA flow diagram: for Objective (a) – Humanistic Burden NASH-cirrhosis 3015 records were 
identified from databases. After removal of duplicates, 1809 records were screened. Eligibility 
assessment of texts, plus 5 grey literature studies, resulted in 31 studies being included in the 
humanistic burden of NASH-cirrhosis synthesis.  
Records identified through database 
searching 
(n= 3015) 
Additional records identified through 
other sources 
(n = 3) 
Records after duplicates removed 
(n = 1809) 
Records screened 
(n = 1809) 
Full text articles assessed 
for eligibility  
(n = 122) 
Full text articles excluded 
with reasons 
(n = 96) 
Studies included from grey 
literature searching 
(n = 5) 
Studies included in synthesis  
(n = 31) 
(n = 26) 
 




















Study characteristics  268 
Humanistic burden of NASH-cirrhosis  269 
Supplementary Table 2, (supplementary material – Appendix 3) reports the characteristics 270 
of the identified literature that met the inclusion criteria for this objective. The majority of 271 
data sources (studies) were conducted in the USA (n=18, 58%), no more than three studies 272 
were conducted in any other country and in total; studies were conducted in eight different 273 
mainly western countries.  Nine studies were specifically aimed at determining HRQoL (14, 274 
25, 27-33); 13 studies were focused on specific related symptoms such as varices, pain or 275 
overall physical/mental symptoms (34-44); two were case studies each describing the 276 
experience of a single patient (45, 46); three studies were concerned with PROM 277 
development and validation (47-49). Within the identified studies, one was an opinion piece 278 
Fig 2: PRISMA flow diagram: for Objective (b) – PROMS F4 A second database search identified a 
further 545 studies in addition to search one (objective (a)). After removal of duplicates, 2355 records 





searching in addition to 
Search 1 
(n = 545) 
Records after 
duplicates removed (n= 
2355) 
Full text articles 
assessed for eligibility 
(n = 28) 
Full text articles 
excluded with 
reasons 
(n = 8) 





through database  
(n = 3015) 
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(50); five were conference abstracts (32, 33, 42-44) and five were patient blogs/stories (51-279 
55).  280 
The majority of the studies (n = 19) specifically identified the inclusion of NASH-cirrhosis 281 
patients (14, 28-30, 33, 35-41, 43, 45, 46, 49, 51, 55, 56), four studies were assumed to refer 282 
to NASH-cirrhosis - these studies grouped ‘other’ liver disease aetiologies as one group (32, 283 
34, 43, 47); the final seven studies (25, 42, 48, 50, 52-54) only referred to their target group 284 
as  ‘cirrhosis patients’.   285 
Comorbidities, complications and symptoms  286 
The main comorbidities (where reported in studies, but not included in Supplementary 287 
Table 2) of patients with cirrhosis were Type II Diabetes; obesity; and cardiovascular disease, 288 
and hypertension.  For the complications of variceal bleeding, ascites three reports for each. 289 
The key symptoms (where reported by included reports) were stated to be abdominal 290 
symptoms; abdominal pain; lack of energy; tiredness, pain; and sleep symptoms.  291 
HRQoL concepts  292 
Where explicitly reported, the HRQoL concepts are described as reported by the study. 293 
Where HRQoL concepts were not reported, or not directly referred to as HRQoL, such as for 294 
example in the grey literature, the possible concepts were discussed within the team and 295 
described as ‘researcher interpretation (RI)’. The most commonly reported areas of HRQoL 296 
impact related to the following concepts; related to physical health /functioning; emotional 297 
health/worry; pain; mental health and general health. 298 
NASH-cirrhosis in relation to cirrhosis of differing aetiology 299 
A finding of the review was that some studies reported symptoms correlating with the 300 
severity but not aetiology of liver disease.  Therefore, they did not specifically refer to 301 
NASH-cirrhosis.   An example of this was for gastrointestinal symptoms (28). This did not 302 
apply to all symptoms.  For example for the relationship between pain and the cause of 303 
disease, one study specifically excluded patients with other known causes of pain.  This 304 
study reported that patients with NASH or hepatitis C associated cirrhosis were more likely 305 
to suffer pain than, patients with alcoholic liver disease cirrhosis (39). In studies focusing on 306 
HRQoL, it was found that NASH-cirrhosis patients had worse physical health compared to 307 
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other NAFLD groups (27). Patients with NASH and cirrhosis reported “more impairment” on 308 
physical and mental status scales compared to non-cirrhotic patients (14). HRQoL has been 309 
reported to be significantly lower in patients with cirrhosis compared to a ‘healthy 310 
population’ and this was significantly worse in patients with increased clinical severity of the 311 
disease measured by Child-Pugh class.  (25).  Excessive daytime sleepiness was found to be a 312 
burden for 40% of cirrhotic patients in a study by Sobhonslidsuk et al (2011) (42).  313 
Compensated and decompensated patients 314 
In the studies that considered patients with compensated/decompensated cirrhosis, using 315 
the EQ-5D-3L, it was reported that decompensated cirrhosis patients had higher risk of 316 
having problems with mobility, self-care and usual activities compared to ‘healthy subjects’ 317 
(32).  Edula et al (2014), in their case study of a patient with NASH cirrhosis asserted that 318 
bleeding from gastro-oesophageal varices ‘can often present as a first decompensating 319 
event’ (57) for patients with previously identified compensated disease. NASH-cirrhosis 320 
patients were also reported to be at risk of bleeding from varices (30/47 patients) in the 321 
Japanese study by Nakamura et al (58).   322 
Grey literature and blogs 323 
Findings from the grey literature blogs highlighted perspectives both from the NASH-324 
cirrhosis patient (n=3) and the patient’s spouse/family members (n=2). With the exception 325 
of one report, where a patient had not suffered any symptoms before diagnosis (54), 326 
symptoms were often described as progressing quickly or in multitude. Reported symptoms 327 
included loss of appetite, weight loss, fatigue, pain, itchy skin and confusion. Two of the 328 
patients (52, 53) were forced to give up work. Not being able to perform routine daily tasks 329 
impacted considerably on the patients’ everyday quality of life (51-53). The overall 330 
impressions garnered from the blogs were of shock, disbelief and of a life being put on hold. 331 
It was reported that, one patient had died (51), one had received a living donor transplant 332 
(53), one was on the waiting list for a transplant (52), and the remaining two (54, 55) were 333 
‘living’ with NASH-cirrhosis. Also apparent was the lack of knowledge surrounding NASH 334 
liver disease; for their families this appeared to be a key issue.  335 
Page 15 of 31 
 
In summary, patients with cirrhosis are reported to suffer from a lower HRQoL than the 336 
‘healthy’ population and non-cirrhotic NAFLD patients particularly in respects to physical 337 
health/functioning, emotional health and worry, and mental health.  338 
PROMs identified 339 
Thirteen PROMs were identified in the literature as used to assess burden of disease in  340 
patients with NASH cirrhosis: Short Form Health Profile (SF-36), Nottingham Health Profile 341 
(NHP), Chronic Liver Disease Questionnaire (CLDQ), Liver Disease Quality of Life 342 
Questionnaire (LDQOL), Fatigue Impact Scale (FIS), Epworth Sleepiness Scale (ESS), Patient 343 
Reported Outcome Measurement Information System Health Assessment Questionnaire 344 
(PHAQ), Chronic Liver Disease Questionnaire-NAFLD (CLDQ_NAFLD), Liver Disease Symptom 345 
Index (LDSI-2.0), World Health Organisation Quality of Life (WHOQOL-BREF), Self-rating 346 
Anxiety Scale (SAS), Self-rating Depression Scale (SDS) and EQ-5D-3L. Four of these were 347 
liver disease-specific: the Chronic Liver Disease Questionnaire (CLDQ) (47), the Chronic Liver 348 
Disease Questionnaire – non-alcoholic fatty liver disease (CLDQ-NAFLD) (59), the Liver 349 
Disease Quality of Life Questionnaire (LDQOL) (60) and the Liver Disease Symptom Index 350 
(LDSI 2.0) (61). No PROM specifically developed for NASH and cirrhosis was identified. 351 
PROMs were selected for the quality assessment that were most likely to meet FDA 352 
requirements. A key requirement of the FDA guidance is that instruments should be 353 
developed with input from the target population. As the generic PROMs were not 354 
developed based on input from patients with liver disease these were not included in the 355 
quality assessment. A critical appraisal is reported for the following selected PROMs: CLDQ-356 
NAFLD, LDSI 2.0, LDQOL as used in studies across spectrum of NASH; and one symptom-357 
specific PROM (Fatigue Impact Scale - FIS) (62). The FIS was included as it assesses fatigue, 358 
which was identified during the review as being a prominent symptom in this patient 359 
population and its psychometric properties have been evaluated extensively.  (63-65).  360 
Quality assessment of PROMs 361 
CLDQ-NAFLD 362 
The CLDQ (47) is a liver disease-specific PROM, developed in 1999, comprising 29 items 363 
across six domains: abdominal symptoms, activity, emotional, fatigue, systemic symptoms 364 
and worry.  It was developed in a group of patients with an established diagnosis of chronic 365 
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liver disease and various aetiologies included hepatocellular liver disease, chronic hepatitis 366 
C, chronic hepatitis B, primary biliary cirrhosis, primary sclerosing cholangitis, viral hepatitis 367 
B and C – related cirrhosis, alcohol related cirrhosis and other types of liver disease, with no 368 
specific mentioning of NAFLD or NASH (45). The initial development took place before the 369 
publication of FDA guidance for PROMs and was completed via experts with some 370 
subsequent patient review, rather than through traditional concept elicitation processes. A 371 
list of health-related problems likely to be relevant to patients with chronic liver disease was 372 
developed by hepatologists and subsequently presented to 60 chronic liver disease (CLD) 373 
patients, which resulted in the final version of the questionnaire.  374 
The CLDQ-NAFLD (59), developed in 2017, is an extended version of the CLDQ with an 375 
additional seven questions that focus the PRO more towards NAFLD.  The development 376 
work for these seven additional question involved presenting 75 items to a sample of 25 377 
patients with NAFLD.  Of these 25, 20 had NASH and five were diagnosed with histological 378 
cirrhosis. Further validation involved a psychometric evaluation in a sample of 104 patients 379 
with biopsy or imaging-proven diagnosis of NAFLD.  Of these 104 patients, 50% were 380 
diagnosed with histological NASH and 15% having compensated cirrhosis. The 7 additional 381 
questions were added to existing CLDQ questions following an item reduction step.  Domain 382 
scores and an overall score are presented on a 1–7 Likert scale with higher values 383 
representing better quality of life (QoL).  384 
The development process followed for the CLDQ-NAFLD was not clearly described in the 385 
study report and so it does not meet the most recent standards for PROM development. In 386 
particular, the concept elicitation stage involving patients is not described and the rationale 387 
for the selection of 75 original items is not explained.  Construct validity was however 388 
reported to be adequate; worse scores being correlated with increased disease severity in 389 
all scales. Correlations were reported between the Activity, Emotional, Fatigue and Systemic 390 
Symptoms domains of CLDQ-NAFLD and similar domains of SF-36 measure, providing 391 
evidence of convergent validity of the measure. The CLDQ-NAFLD was able to discriminate 392 
between NAFLD subjects with obesity, type 2 diabetes and metabolic syndrome, but no 393 
evidence was presented of a difference between cirrhotic and non-cirrhotic patients (59). 394 
The Cronbach’s alpha coefficient was reported to be between 0.74 and 0.9 suggesting good 395 
to excellent internal consistency of the domains. Test-retest reliability data came from a 396 
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small subgroup of patients (n=27) and so may lack sufficient statistical power to detect 397 
differences. Furthermore, no formal evidence of content validity for a NASH population has 398 
been published to date.  399 
LDQOL 1.0 400 
The LDQOL 1.0 (60) consists of a total of 111 questions: 36 generic questions taken from the 401 
SF-36 (66) and 75 questions grouped in 12 liver disease-specific multi-item scales. The recall 402 
period is 4 weeks and all questions are scored on a 0-100 visual analogue scale with higher 403 
scores representing better QoL.  404 
The tool was developed in a group of 15 chronic liver disease patients (aetiologies included 405 
hepatitis C, hepatitis B, alcoholic liver disease, autoimmune hepatitis, primary sclerosing 406 
cholangitis, cryptogenic cirrhosis, and biliary atresia) awaiting liver transplantation and 407 
psychometric properties established in a cohort of 221 subjects with advanced chronic liver 408 
disease (hepatitis C, hepatitis B, alcoholic liver disease, primary biliary cirrhosis, primary 409 
sclerosing cholangitis, cryptogenic cirrhosis etc.) (60). Content validity was tested by 410 
organising focus groups with chronic liver disease patients, consulting hepatologists and 411 
gastroenterologists as well as reviewing the literature on HRQoL in general (60). 412 
Authors report high internal consistency coefficients (Cronbach's α) between 0.62 and 0.95, 413 
suggesting potential item redundancy for some domains, with 19 scales having > 0.70, 414 
except for the quality of social interaction scale. Multi-trait scaling analysis is reported to 415 
provide strong support for item discrimination across scales.  Correlations among SF-36 416 
items and liver-specific items ranged from 0.14 to 0.78. Authors report 17 out of 20 scales 417 
statistically associated with worse scores, the scales that did not reach this level of 418 
significance included hopelessness, loneliness and the quality of social interaction. Worse 419 
scores were associated with higher severity of self-reported symptoms and higher number 420 
of disability days in the previous month. 421 
There was evidence of associations between physical role limitation, pain, fatigue scales and 422 
worse self-reported liver disease symptoms were found in the liver disease-specific scales of 423 
the LDQOL 1.0. This suggests that either the tool is able to capture liver disease-specific 424 
quality of life information that a generic PRO measure would not be able to obtain in the 425 
CLD population or it could also show major item redundancy. The main limitation of the tool 426 
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is the length of the scale as a 111-item questionnaire may be impractical to employ. 427 
Additionally, the 4-week recall period reduces the suitability of the instrument for use in 428 
product label claims. Furthermore, given that this instrument was originally developed with 429 
patients with advanced chronic liver disease, it could be argued that the main value of this 430 
instrument may be in a decompensated cirrhotic population. 431 
LDSI 2.0 432 
The LDSI 2.0 (61) is a liver disease-specific questionnaire consisting of 24 items with a recall 433 
period of one week. The tool was developed in 2004 before the publication of the FDA 434 
guidance and psychometrically tested in a large cohort of 1175 subjects with chronic liver 435 
disease. The tool is a modified version of the original LDSI (67) measure with “jaundice”, 436 
“depression” and “worry about family situation” added to the list of items after 437 
consultations with a liver patients’ organisation. 438 
Nine items measure severity of itch, joint pain, pain in the right upper abdomen, sleepiness 439 
during the day, worry about family situation, decreased appetite, depression, fear of 440 
complications and jaundice experienced within the previous week. Nine other items 441 
measure the impact of these symptoms on person’s daily activities. Six additional items 442 
concern memory problems, change of personality, financial affairs, change in use of time, 443 
reduced sexual activity and reduced sexual interest. All items are individually scored on a 0-444 
5-point scale ranging from “not at all” to “to a high extent”.  445 
The assessment of content validity is not described in the original paper. Authors report 446 
adequate feasibility, test-retest reliability and construct validity in a population of chronic 447 
liver disease patients (61). High correlations were detected between the “Joint pain”, 448 
“Sleepiness during the day” and “Depression” symptoms severity and corresponding 449 
hindrance items. However, authors demonstrated larger impact of hindrance items on 450 
overall quality of life score than the symptom severity items, which leads to the conclusion 451 
that different items of the instrument measure different aspects of quality of life. 452 
Internal consistency is reported as high with Cronbach’s α > 0.79. Spearman correlations 453 
suggested strong convergent relations between symptom severity items and their 454 
accompanying symptom hindrance items ( 0.52 - 0.80) (61) 455 
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Fatigue Impact Scale (FIS) 456 
The Fatigue Impact Scale (FIS) (62) was developed in 1994 in a group of patients with 457 
multiple sclerosis (MS). Rather than measuring the level of fatigue itself, the instrument 458 
reflects a patient’s perception of the functional limitation due to fatigue experienced within 459 
the previous month. The tool is composed of 40 items grouped into three scales: cognitive, 460 
physical and psychosocial functioning. All items are scored on a 0-4 scale ranging from “no 461 
problem” to “extreme problem”.  462 
Internal consistency is reported to be high for overall scores and the three subscales 463 
(Cronbach's α ≥ 0.87) as well as the test-retest reliability (0.72-0.83) (62). The tool was able 464 
to discriminate between the three patient groups (patients with MS; with chronic fatigue 465 
and mild hypertension groups) based on both overall score and specific FIS items. Further 466 
validity of the tool has been established in patients with chronic fatigue syndrome, primary 467 
biliary sclerosis, chronic hepatitis C and multiple sclerosis (68), but no validation in NASH 468 
population has ever been performed.  469 
Table 1 presents a summary comparison of the PRO measurement tools included in the 470 
assessment using both FDA and COSMIN criteria.  471 
  472 
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Table 1 Comparison of selected PRO measurement properties to FDA and COSMIN recommended standards. The table presents the relevant PROs which were evaluated for the review. 
Described are: content/item source; item/domains; recall period; construct validity and other validity; reliability; instrument modification and; main limitation. It can be seen that the PROs 
have limitations relating to population group, tool practicality, evidence or validation. 
PRO Content / item Source Items/domains Recall period Construct validity and other 
validity 
Reliability  Instrument 
modification 
Main limitation 
CLDQ-NAFLD Items were developed using 
a variety of sources (HRQOL 
tools, focus groups, patient 
interviews – 25 subjects 
with NAFLD, among them 
20% with histological 
cirrhosis  
 
Validated in 104 NAFLD 
patients, among them 15% 
with compensated cirrhosis 





2 weeks  Construct Validity: Domains 
highly correlated with Short 
Form 36 questionnaire (SF-36): 
Activity, Emotional, Fatigue 
and Systemic Symptoms 
Psychometrically evaluated in 
a group of NAFLD patients 
(n=104). 
Known-Groups Validity: Worse 
scores correlated with 
increased disease severity in 
all scales; unable to 
discriminate between cirrhotic 
and non-cirrhotic patients. 
Not validated in a cohort of 
advanced liver cirrhosis 
patients; not validated in 
NASH 
Tested and retested in a 
small subgroup of NAFLD 
patients (n=27; 5-19 
weeks apart) – non 
statistically significant. 
Internal consistency: 
Cronbach’s α 0.74-0.90  
 
Modified version of 
CLDQ 
Lack of evidence of 
content validity 
within a NASH 
population 
LDQOL 1.0 Developed after conducting 
focus group interviews with 
15 patients awaiting liver 
transplantation and 
literature search on HRQoL 
in liver disease 
Input from patient focus 
groups combined with 
views of gastroenterologists 
and hepatologists and 
literature search of HRQoL 
SF36 + 12 disease-
targeted scales (75 
items): Symptoms of 
liver disease, Effects of 
liver disease, 
Concentration, 
Memory, Quality of 
Social Interaction, 
Health Distress, Sleep 
Problems, Loneliness, 
Hopelessness, Stigma 
of Liver Disease, 
Sexual Functioning, 
4 weeks Psychometrically evaluated in 
a group of end stage liver 
disease patients. 
Known-groups validity: Worse 
scores correlated with worse 
Child-Pugh class, worse self-
rated liver disease severity and 
higher number of disability 
days 
Internal consistency: 
Cronbach’s α 0.62-0.95.  
n/a The tool is 
impractical to use 
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Sexual Problems. 
LDSI 2.0 Items were developed in a 
large group of liver disease 
patients (patient 
interviews) 
24 items: 9 items 
measure severity of 
symptoms (itch, joint 
pain, pain in the right 
upper abdomen, 
sleepiness during the 
day, worry about 
family situation, 
decreased appetite, 
depression, fear of 
complication, 
jaundice); 9 items 
measure the impact of 
these symptoms on 
person’s daily 
activities; 6 items 
evaluate memory 
problems, change of 
personality, financial 
affairs, change in use 
of time, reduced 
sexual activity and 
reduced sexual 
interest  
1 week Construct validity: tested in 
comparison with Short Form-
36 (SF-36) and the 
Multidimensional Fatigue 
Index-20 (MFI-20), showed low 
to moderate correlations 
indicating a slight to moderate 
overlap between the 
information given by the LDSI 
and the other two 
questionnaires 
Spearman correlations 
reported between symptom 
severity and related hindrance 
items ranged between 0.52-
0.80. 
Psychometrically evaluated in 
a general population of 
chronic liver disease patients 
(n=1175). 
 
Test-retest reliability in a 
small group of patients 





Modified version of 
LDSI 
Lack of evidence of 
content validity 
FIS Developed on the basis of 
existing fatigue 
questionnaires in a group of 
patients with multiple 
sclerosis (n=30) (patient 
interviews) 
Designed in accordance 
with the taxonomy on 
quality of life in clinical 
trials (69) 




functioning (40 items) 
1 month Construct  Validity: statistically 
significant correlations 
between the total FIS and 
Sickness Impact Profile (SIP) 
(generic HRQoL measure) 
score  
Evaluated in a group of 
patients referred to the 
Infectious Disease Unit for 
investigation of fatigue 
Internal consistency: 
Cronbach’s α 0.98 
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Discussion  407 
NAFLD is now recognised to affect approximately 25% of the global adult population, and so 408 
is a leading cause of liver dysfunction and cirrhosis (1). At present, there are no licenced 409 
pharmacological therapies for NASH and so management focusses on lifestyle modification 410 
to achieve weight loss by diet and exercise. Although prior to hepatic decompensation, 411 
NAFLD/NASH is generally considered asymptomatic, this dogma is increasingly being 412 
brought into question (70, 71). An holistic approach to patient care implies a need for 413 
clinicians to appreciate the wider consequences of a NASH diagnosis, including how its 414 
psychosocial and symptom burden impacts on HRQoL and the ability of patients to make 415 
substantive lifestyle changes, even prior to hepatic decompensation. Such knowledge, 416 
objectively measured, not only informs our understanding of the lived experience of the 417 
disease but allows the impact of novel therapies on HRQoL to be measured; addressing the 418 
first tenant of the FDA’s patient-focussed drug development, that treatment must benefit 419 
how patients “feel, function and survive” (11). The aim of this review was firstly, to identify 420 
humanistic burden of disease in patients with diagnosed NASH and compensated cirrhosis, 421 
and secondly, to identify which instruments, generic or disease specific PROMs have been 422 
used to assess the impact of NASH-cirrhosis and have sufficient evidence to render them 423 
suitable for use in support of regulatory label claims.   424 
The limited heterogeneous literature meant that the level of detail in the reporting varied 425 
greatly between studies, which made synthesis difficult. Studies were included even if they 426 
did not specifically refer solely to NASH-cirrhosis.  This is because several studies reported 427 
findings correlating with the severity but not the aetiology of liver disease.    428 
From the included studies, several common themes can be identified.   429 
Where reported, type 2 diabetes was cited as the main comorbidity for patients with liver 430 
disease, this was followed by obesity. Obesity and insulin resistance are well documented 431 
risk factors for developing NAFLD and approximately 85% of NAFLD patients will also have 432 
one of these comorbidities (72). Several symptoms were reported as being problematic for 433 
patients with liver disease, these included: abdominal pain, general pain, lack of energy, 434 
tiredness and sleep symptoms. Frequent comorbid conditions raise the possibility that 435 
patient burden is impacted by an illness other than NASH. However, due to associated 436 
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conditions (e.g. overweight and diabetes) and the high prevalence of other comorbidities, it 437 
is challenging to assert that effects are solely down to NASH.  438 
Although it could be argued that the differentiation and identification of symptoms between 439 
different comorbidities, i.e. liver disease and diabetes could be problematic (73); cirrhotic 440 
patients were reported as having worse physical health/functioning (27), emotional health, 441 
mental health (50), and were reported to experience more pain than non-cirrhotic NAFLD 442 
patients (39). Indeed, in one study aiming to determine the factors relating to disability in 443 
cirrhotic outpatients, pain related disability was reported to be ‘nearly universal’ (44) .  444 
Nonetheless, despite many studies reporting the key HRQoL concepts, details of the impact 445 
of these findings on patients’ everyday work and family life are lacking. Only nine of the data 446 
sources specifically aimed to determine HRQoL.  Findings from the patient blogs provided a 447 
more detailed insight of the personal impact of living with NASH-cirrhosis such as ‘shock’, 448 
‘disbelief’ and ‘life being put on hold’. The importance of HRQoL concepts being from a 449 
patient or clinical perspective has been highlighted (13). This suggests that further studies, 450 
especially those incorporating a qualitative (60) element, would be valuable in determining 451 
the full humanistic burden of living with NASH-cirrhosis. Also lacking are studies which focus 452 
specifically on NASH-cirrhosis or which differentiate between compensated and de-453 
compensated cirrhosis patients; whether this is due to lack of studies with this population or 454 
the way in which findings are presented in identified studies is unclear. Additionally, the 455 
majority of studies meeting the inclusion criteria were conducted in the USA and it is known 456 
that cultural factors have the potential to influence the burden of disease; this raises the 457 
need for further studies in other geographical and cultural settings. 458 
PROMs 459 
The presented PRO instruments (apart from LDSI 2.0) have all been used in clinical trials for 460 
several years. However, they all have limitations in terms of their development and 461 
psychometric properties. In part, this may be because they were developed prior to the 462 
publication of the FDA guidance for PRO instruments for use in product labelling. Hence, 463 
published documentation supporting the development, use, content validity and 464 
interpretation of results of LDQOL, FIS and LDSI 2.0 instruments lacks the detail required by 465 
current FDA guidance. CLDQ-NAFLD is a relatively new PROM and it is the only PRO 466 
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instrument that has been specifically developed to be used in the NAFLD population. 467 
However, the lack of evidence of the tool’s content validity within a NASH population is a 468 
significant limitation of the CLDQ-NAFLD and means that the appropriateness of its use 469 
amongst a cirrhotic population is not known.  As a result, none of the PRO measures 470 
described meet the current FDA guidance, therefore they cannot be considered suitable for 471 
use as a PRO in cirrhotic NASH clinical trials, where the intention is to seek a PRO-based 472 
product label claim. 473 
Strengths and limitations 474 
This targeted review, focusing on NASH-cirrhotic patients, made use of standard review 475 
processes which, added rigour to the scoping process. For example, having two reviewers 476 
work on each stage of the review process, and the search strategy was developed in 477 
consultation with an information specialist. The heterogeneous nature of the literature and 478 
the different ways in which data was reported made synthesis challenging. Based on the 479 
available literature, it was also not possible to evaluate the relative impact of common 480 
comorbid health conditions in patients with NASH cirrhosis e.g. type 2 diabetes. 481 
Furthermore, only English language studies were retrieved and reviewed. A quality 482 
assessment of the PRO instruments identified was also conducted. However, it is 483 
acknowledged that some relevant studies may have been missed by our search strategy. 484 
Conclusions  485 
The objective of this study was to describe the humanistic burden of NASH in the cirrhotic 486 
population and to determine which PROMs (if any) were used with this group. Patients with 487 
cirrhosis are reported as having lower HRQoL and cirrhosis is associated with poorer 488 
physical health. However, the findings lacked detail of everyday impact on patients’ lives. 489 
Some additional symptoms were identified, namely: abdominal symptoms, muscle cramps 490 
and depression/anxiety. Further qualitative studies with this patient population would be of 491 
benefit to understand how this disease affects patient’s daily lives and if the experience of 492 
this group differs from the non-cirrhotic NASH population. Currently, a number of HRQoL 493 
tools are available to measure the impact of the disease in patients with chronic liver 494 
conditions, however, the most commonly used measures do not comply with the most 495 
recent standards of the US FDA and/or are not validated to meet the needs of the 496 
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population of NASH-cirrhosis patients. It is important to assess the impact of the disease-497 
specific symptoms and complications, particularly in a population of NASH patients as non-498 
specific PRO tools will likely miss those particular symptoms experienced by NASH-cirrhosis 499 
population. Therefore, there is a clear need for a fully validated disease-specific PRO 500 
measure for use in NASH patients that can also be used in the compensated cirrhotic NASH 501 
population. 502 
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